OPKO Health, Inc.
NASDAQ:OPKBiotechnology
+$0.01 today
- Market cap
- $1.25B
- Beta
- 1.49
- P/E (TTM)
- -5.1
- EPS (TTM)
- -$0.28
Volume 3.06M
Average 2.59M
OPK EBITDA Margin
EBITDA as a percentage of revenue.
OPKO Health, Inc.NASDAQ: OPK
EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026
EBITDA Margin widens to -22.4%
EBITDA Margin was -22.4% in Q1 FY2026, up 0.6 pp from a year earlier. On a trailing-twelve-month basis it was -6.0%, down 27.8 pp year over year. Over 3 fiscal years it widened by 20.2 pp.
Context
- EBITDA Margin widened in 2 of the last 3 fiscal years.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 4 analysts of -9.1% for the fiscal year ending Dec 2026, down from -6.8% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -22.4%-13.5 pp QoQ
- Last fiscal yearDec 2025
- -6.8%-25.8 pp YoY
- LTMMar 2026
- -6.0%-27.8 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +0.6 pp | +28.5 pp | +27.9 pp |
| 1 year | -25.8 pp | -2.2 pp | +23.5 pp |
| 3 years | +20.2 pp | -24.2 pp | -44.3 pp |
| 5 years | +5.3 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -6.8%
- Year-over-year change
- -25.8pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -6.8% | -25.8pp |
| FY2024 | 2024-12-31 | 19.0% | +26.6pp |
| FY2023 | 2023-12-31 | -7.6% | +19.4pp |
| FY2022 | 2022-12-31 | -27.0% | -31.7pp |
| FY2021 | 2021-12-31 | 4.7% | — |
EBITDA Margin vs competitors
How OPK compares with its peers on the latest reported figures
- OPK's LTM Mar 2026 EBITDA Margin of -6.0% is the 4th highest of the 11 companies compared; the peer median is -15.6%.
- Its year-over-year change of -27.8 pp is the 9th highest of 11, against a peer median of +2.8 pp.
- Over three fiscal years its change of +20.2 pp compares with a peer median of +49.9 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
BLLNBillionToOne, Inc. | LTM Jun 2026 | 12.6% | +21.8 pp | — |
| LTM Jun 2026 | 1.7% | +5.8 pp | +10.8 pp | |
| LTM Mar 2026 | -0.2% | -12.0 pp | +45.9 pp | |
| LTM Mar 2026 | -6.0% | -27.8 pp | +20.2 pp | |
| LTM Jun 2026 | -6.6% | +4.2 pp | +53.9 pp | |
| FY2025 | -13.0% | +11.5 pp | +85.2 pp | |
| LTM Mar 2026 | -18.3% | -9.7 pp | -49.4 pp | |
| LTM Mar 2026 | -18.9% | +1.5 pp | +75.6 pp | |
| LTM Sep 2026 | -34.5% | +4.7 pp | +98.7 pp | |
| LTM Mar 2026 | -40.3% | -32.6 pp | -27.6 pp | |
| LTM Mar 2026 | -132.6% | -47.0 pp | — | |
| Peer median (excluding OPK) | -15.6% | +2.8 pp | +49.9 pp | |
Competitors are the stored peer set for OPK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.77B | 1B | 863.5M | 713.14M | 606.88M |
| Cost of Revenue | 1.19B | 715.98M | 545.37M | 402.11M | 478.83M |
| Gross Profit | 581.52M | 288.22M | 318.13M | 311.03M | 128.05M |
| Gross Margin | 32.8% | 28.7% | 36.8% | 43.6% | 21.1% |
| Research & Development | 76.85M | 73.89M | 89.59M | 105.21M | 124.03M |
| Selling, General & Admin | 468.86M | 372.67M | 300.56M | 304.22M | 223M |
| Operating Expenses | 562.77M | 514.47M | 475.15M | 463.1M | 347.04M |
| Depreciation & Amortization | 78.72M | 108.66M | 105.3M | 98.18M | 91.63M |
| EBITDA | 83.57M | (270.81M) | (65.52M) | 135.28M | (41.3M) |
| EBITDA Margin | 4.7% | -27.0% | -7.6% | 19.0% | -6.8% |
| Operating Income | 18.75M | (226.25M) | (157.02M) | (152.07M) | (218.99M) |
| Operating Margin | 1.1% | -22.5% | -18.2% | -21.3% | -36.1% |
| Interest Income | 28K | 1.98M | 3.98M | 8.43M | 14.81M |
| Interest Expense | 18.88M | 12.06M | 13.51M | 47.47M | 108.46M |
| Other Income / Expenses | (33.4M) | (165.65M) | (27.41M) | 141.7M | (22.41M) |
| Income Before Tax | (14.65M) | (391.9M) | (184.43M) | (10.36M) | (241.39M) |
| Pre-Tax Margin | -0.8% | -39.0% | -21.4% | -1.5% | -39.8% |
| Income Tax Expense | 15.49M | (63.5M) | 4.44M | 42.84M | (15.71M) |
| Net Income | (30.14M) | (328.41M) | (188.86M) | (53.22M) | (225.68M) |
| Net Margin | -1.7% | -32.7% | -21.9% | -7.5% | -37.2% |
| EPS (Basic) | (0.05) | (0.46) | (0.25) | (0.08) | (0.30) |
| EPS (Diluted) | (0.05) | (0.46) | (0.25) | (0.08) | (0.30) |
| Weighted Avg Shares | 648.08M | 719.06M | 751.77M | 694.02M | 751.13M |
| Weighted Avg Shares (Diluted) | 648.08M | 719.06M | 751.77M | 694.02M | 751.13M |
OPKO Health, Inc.
NASDAQ:OPK
Intrinsic Alpha fair value
Locked
Current Price
$1.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.